Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; sunset yellow fcf; purified talc; quinoline yellow aluminium lake; lactose monohydrate; maize starch; magnesium stearate - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical. hypertension. oral lasix may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately control

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - indapamide hemihydrate, quantity: 2.5 mg - tablet, sugar coated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; purified talc; calcium carbonate; titanium dioxide; sucrose; acacia; ethyl acetate; purified water; stearic acid; industrial methylated spirit; polyvinyl acetate phthalate; shellac; white beeswax; carnauba wax - management of essential hypertension. it may be tried as the sole therapeutic agent in the treatment of mild to moderate hypertension. normally indapamide is used as the initial agent in multiple drug regimens.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; stearic acid; maize starch; lactose monohydrate - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; microcrystalline cellulose; maize starch - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

Israel - inglês - Ministry of Health

padagis israel agencies ltd, israel - azathioprine - film coated tablets - azathioprine 25 mg - azathioprine - azathioprine - immunosuppressive agent used in transplantation surgery for suppression of graft rejection. for special cases of rheumatoid arthritis- not responsive to other agents- and only by rheumatology experts in hospitals or rheumatic clinics.

Israel - inglês - Ministry of Health

padagis israel agencies ltd, israel - azathioprine - film coated tablets - azathioprine 50 mg - azathioprine - azathioprine - immunosupressive agent used in transplantation surgery for suppression of graft rejection. for special cases of rheumatoid artritis, not responsive to other agents, and only by rheumatology experts in hospitals or rheumatic clinics.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; magnesium stearate; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; copovidone; magnesium stearate; hypromellose; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; carmellose sodium; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin